Abstract
Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Letters in Drug Design & Discovery
Title: Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX
Volume: 6 Issue: 8
Author(s): Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny and Kamil Kuca
Affiliation:
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Abstract: Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Export Options
About this article
Cite this article as:
Karasova Zdarova Jana, Bajgar Jiri, Novotny Ladislav and Kuca Kamil, Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX, Letters in Drug Design & Discovery 2009; 6 (8) . https://dx.doi.org/10.2174/157018009789353419
DOI https://dx.doi.org/10.2174/157018009789353419 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Multiple Roles of Transient Receptor Potential (TRP) Channels in Inflammatory Conditions and Current Status of Drug Development
Current Topics in Medicinal Chemistry The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Current Topics in Medicinal Chemistry Cytochromes P450 in Brain: Function and Significance
Current Drug Metabolism Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Current Neuropharmacology Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research The Endocannabinoid System in Huntingtons Disease
Current Pharmaceutical Design Progress in the Development of Melanocortin Receptor Selective Ligands
Current Pharmaceutical Design Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain
Current Molecular Medicine PEDF in Angiogenic Eye Diseases
Current Molecular Medicine